300685.SHE Amoy Diagnostics Co Ltd

300685.SHE trades 93.7% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

No fundamental analysis for Amoy Diagnostics Co Ltd yet.

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx comprehensive panel, a sequencing-based test capable of detecting a range of alterations; Amoy…

2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.

Amoy Diagnostics Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)

Dividend yield

1.59%

Forward dividend

0.45 CNY

Payout ratio

33.2%

Ex-dividend date

May 18, 2026

From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.

Last stock split: 1.8:1 on May 31, 2022.

Company name

Amoy Diagnostics Co Ltd

Ticker

300685.SHE

ISIN

CNE1000034D3

Exchange

Shenzhen Stock Exchange

Sector

Healthcare

Industry

Biotechnology

Employees

1,175

Fiscal year end

December

Address

No. 39 Dingshan Road, Xiamen, China, 361027

Phone

86 59 2680 6830

Website

amoydx.com

About Amoy Diagnostics Co Ltd

Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx comprehensive panel, a sequencing-based test capable of detecting a range of alterations; AmoyDx HRD complete panel, detects genetic aberrations across HRR genes and HRD status; AmoyDx master panel, a comprehensive genomic profiling assay; AmoyDx BRCA Pro panel, covers various protein coding regions, intron/exon boundaries, select introns, and UTR regions of the BRCA1 and BRCA2 genes; and AmoyDx handle classic NGS panel, detects multiple gene mutations in cancer patients for treatment. It also provides AmoyDx handle HRR NGS panel for detection of somatic and germline variants; AmoyDx pan lung cancer PCR panel, a tissue-based real-time qPCR assay for in vitro diagnostics; AmoyDx myeloid blood cancer panel; AmoyDx PD-L1 (E1L3N) assay; and AmoyDx handle melanoma NGS panel solutions. In addition, the company offers ALK gene fusions and ROS1 gene fusions, multi-gene mutations, EML4-ALK fusion gene, EGFR/ALK/ROS1 mutations, MET mutation, HER2 mutation, RET gene fusions, KRAS mutation, KRAS/NRAS mutations, NRAS mutation, KRAS/NRAS/BRAF mutations, BRAF mutation, PIK3CA five mutations, microsatellite instability, PIK3CA mutation, human papillomavirus genotyping, JAK2 mutation, TERT/HRAS mutations, EGFR 29 mutations, EGFR mutation, ROS1 gene fusions, NTRK gene fusions, BRAF V600 mutations detection kits, as well as DNA and RNA extraction kits under the Super-ARMS and AmoyDx names. Amoy Diagnostics Co., Ltd. was founded in 2008 and is based in Xiamen, China.

• Mr. Jiemin LuoGM & Director · born 1983
• Ms. Ying ChenCFO, Accounting Supervisor & Secretary to the Board of Directors · born 1970
• Mr. Ruan LiDeputy GM, CTO & Director · born 1978
• Mr. Frank Ron ZhengDeputy GM & Director · born 1990
• Mr. Huibin ZhengDeputy General Manager · born 1962
• Mr. Hongyu WangDeputy General Manager · born 1984
• Mr. Shuang YangDeputy General Manager · born 1987